<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712942</url>
  </required_header>
  <id_info>
    <org_study_id>SHAPE</org_study_id>
    <nct_id>NCT04712942</nct_id>
  </id_info>
  <brief_title>Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat</brief_title>
  <official_title>Treatment of MDS/AML Patients With an Impending Hematological Relapse With Azacitidine Alone or in Combination With PEvonedistat - a Randomized Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MDS/AML with MRD and impending relapse after allogeneic stem cell transplantation and/or&#xD;
      conventional chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental arm: pevonedistat in combination with azacitidine Control arm: azacitidine alone&#xD;
&#xD;
      With the following modifications:&#xD;
&#xD;
        -  Patients on the azacitidine arm and still MRD+ at 3 months but without hematological&#xD;
           relapse can cross over to the combination arm&#xD;
&#xD;
        -  Cross over into the combination arm is possible any time up to 9 months of study&#xD;
           treatment if initially responding patients (at 3 months) on AZA monotherapy become MRD&#xD;
           positive again&#xD;
&#xD;
        -  Maximum treatment duration of 1 year&#xD;
&#xD;
        -  Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w); azacitidine is given at a&#xD;
           standard dose of 75 mg/m² i.v. or s.c. (d1-7 or 1-5,8,9, q4w)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>With Cross-Over option</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurable residual disease (MRD) status after 3 months of treatment</measure>
    <time_frame>3 months after start of treatment</time_frame>
    <description>To show that pevonedistat and azacitidine are more effective compared to azacitidine alone with regard to achievement of MRD negativity after 3 months of treatment.&#xD;
MRD assessment is carried out as determination of the NPM1mut status or as CD34/CD117 chimerism analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 25 months</time_frame>
    <description>To describe and compare outcome measures between two strategies: pevonedistat and azacitidine in combination versus azacitidine alone with cross over option.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>Time from randomization until hematological relapse or death from any cause (whichever comes first), assessed up to 25 Months.</time_frame>
    <description>To describe and compare outcome measures between two strategies: pevonedistat and azacitidine in combination versus azacitidine alone with cross over option.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment assessed by using the validated questionnaires EORTC QLQ-C30.</measure>
    <time_frame>Time from randomization until hematological relapse or death from any cause (whichever comes first)</time_frame>
    <description>To describe and compare outcome measures between two strategies: pevonedistat and azacitidine in combination versus azacitidine alone with cross over option.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of treatment assessed by using the validated questionnaires EQ-5D-5L.</measure>
    <time_frame>Time from randomization until hematological relapse or death from any cause (whichever comes first), assessed up to 25 months.</time_frame>
    <description>To describe and compare outcome measures between two strategies: pevonedistat and azacitidine in combination versus azacitidine alone with cross over option.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Minimal Residual Disease</condition>
  <arm_group>
    <arm_group_label>pevonedistat + azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pevonedistat in combination with azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azacitidine monotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>administration of azacitidine monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pevonedistat</intervention_name>
    <description>Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles</description>
    <arm_group_label>pevonedistat + azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles</description>
    <arm_group_label>azacitidine monotherapy</arm_group_label>
    <arm_group_label>pevonedistat + azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AML or MDS&#xD;
&#xD;
          -  continuing first CR after conventional intensive chemotherapy OR continuing CR after&#xD;
             alloSCT&#xD;
&#xD;
          -  Confirmed MRD positivity (assessed by central lab) as defined by:&#xD;
&#xD;
               -  NPM1mut status &gt;1% in peripheral blood or bone marrow in NPM1 mutated patients at&#xD;
                  diagnosis or&#xD;
&#xD;
               -  Patients after allogeneic transplantation, who were NPM1 unmutated at diagnosis&#xD;
                  and have a blood or marrow CD34/CD117 chimerism &lt;80%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Compliance with major study procedures&#xD;
&#xD;
          -  Patient does not accept bone marrow sampling during screening, primary end point visit&#xD;
             and after the treatment.&#xD;
&#xD;
          -  Patient does not accept several blood sampling during screening, treatment (up to&#xD;
             bi-daily) and after the treatment.&#xD;
&#xD;
        Safety&#xD;
&#xD;
          -  Inadequate organ function as defined in the list below:&#xD;
&#xD;
               -  White blood cell (WBC) count &gt; 50 Gpt/L before administration of pevonedistat on&#xD;
                  Cycle 1 Day 1&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1.5 Gpt/L&#xD;
&#xD;
               -  Platelets &lt; 100 Gpt/L&#xD;
&#xD;
               -  Albumin &lt; 2.7 g/dL&#xD;
&#xD;
               -  Creatinine clearance &lt; 30 mL/min (Cockcroft und Gault formula)&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5xupper limit of normal (ULN) except in patients with&#xD;
                  Gilbert's syndrome. Patients with Gilbert's syndrome may be enrolled if direct&#xD;
                  bilirubin &gt; 1.5x ULN of the direct bilirubin.&#xD;
&#xD;
               -  Both Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt; 3.0&#xD;
                  ULN&#xD;
&#xD;
          -  ECOG performance status of ≥2&#xD;
&#xD;
        Concomitant Diseases&#xD;
&#xD;
          -  Hematological relapse&#xD;
&#xD;
          -  Liver cirrhosis or severe pre-existing hepatic impairment&#xD;
&#xD;
          -  Known severe cardiopulmonary disease (e.g. unstable angina, congestive heart failure&#xD;
             NYHA III or IV, myocardial infarction within 6 months prior to screening, symptomatic&#xD;
             cardiomyopathy, clinically significant arrhythmia, clinically significant pulmonary&#xD;
             hypertension requiring pharmacologic therapy)&#xD;
&#xD;
          -  Uncontrolled high blood pressure (i.e. systolic blood pressure &gt; 180 mm Hg, diastolic&#xD;
             blood pressure &gt; 95 mm Hg)&#xD;
&#xD;
          -  Confirmed prolonged rate corrected QT interval ≥ 500 msec, calculated according to&#xD;
             institutional guidelines (Screening ECG)&#xD;
&#xD;
          -  Confirmed left ventricular ejection fraction &lt; 50% as assessed by echocardiogram or&#xD;
             radionuclide angiography (Screening TTE)&#xD;
&#xD;
          -  Known moderate to severe symptomatic chronic obstructive pulmonary disease,&#xD;
             interstitial lung disease, or pulmonary fibrosis&#xD;
&#xD;
          -  Active uncontrolled infection or severe infectious disease, such as severe pneumonia,&#xD;
             meningitis, or septicemia&#xD;
&#xD;
          -  Known psychiatric or substance abuse disorders that would interfere with cooperation&#xD;
             with the requirements of the trial.&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV 1/2 antibodies)&#xD;
&#xD;
          -  Known active Hepatitis B (i.e. HBsAg reactive) or Hepatitis C (i.e., HCV RNA&#xD;
             [qualitative] is detected). NOTE: Patients who have isolated positive hepatitis B core&#xD;
             antibody (i.e. in the setting of negative hepatitis B surface antigen and negative&#xD;
             hepatitis B surface antibody) must have an undetectable hepatitis B viral load.&#xD;
             Patients who have positive hepatitis C antibody may be included if they have an&#xD;
             undetectable hepatitis C viral load.&#xD;
&#xD;
          -  Major surgery within 14 days of randomization or a scheduled surgery during study&#xD;
             period&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement&#xD;
&#xD;
          -  Diagnosis or treatment for another malignancy within 2 years before randomization.&#xD;
             (NOTE: Patients with non-melanoma skin cancer or carcinoma in situ of any type are not&#xD;
             excluded if they have undergone resection. Prior diagnosis of myelodysplasia,&#xD;
             myeloproliferative neoplasm, or aplastic anemia and treatment for that diagnosis does&#xD;
             not lead to exclusion)&#xD;
&#xD;
          -  Any evidence of residual disease of another malignancy&#xD;
&#xD;
          -  Patients with uncontrolled coagulopathy or bleeding disorder&#xD;
&#xD;
          -  History or current evidence of any condition, therapy, or laboratory abnormality that&#xD;
             might confound the results of the trial, interfere with the subject's participation&#xD;
             for the full duration of the trial, or is not in the best interest of the subject to&#xD;
             participate, in the opinion of the treating investigator&#xD;
&#xD;
        Unexpected effect of HMA monotherapy&#xD;
&#xD;
          -  Prior HMA failure&#xD;
&#xD;
          -  Prior HMA treatment without subsequent allogeneic transplantation&#xD;
&#xD;
        Interfering Treatments&#xD;
&#xD;
          -  Any ongoing therapy with investigational agents or chemotherapeutic agents active&#xD;
             against MDS or AML&#xD;
&#xD;
          -  BCRP inhibitors (for exceptions, see section 5.7.5) are not permitted during the study&#xD;
             and should be stopped 14 days before first dose of the study drug&#xD;
&#xD;
        Exclusion criteria regarding special restrictions for females of childbearing potential&#xD;
&#xD;
          -  Current or planned pregnancy or nursing women (negative urine or serum pregnancy test&#xD;
             within 3 days prior to receiving study treatment is needed. If the urine test is&#xD;
             positive or cannot be confirmed as negative, a serum pregnancy test needs to be&#xD;
             required.)&#xD;
&#xD;
          -  Female patients of childbearing potential, who are not using or not willing to use 1&#xD;
             highly effective method and 1 additional effective (barrier) method of contraception,&#xD;
             at the same time, from the time of signing the informed consent through 4 months after&#xD;
             the last dose of study drug. Note: Abstinence is acceptable if this is the usual&#xD;
             lifestyle and preferred contraception for the subject.&#xD;
&#xD;
          -  Female patients who intend to donate eggs (ova) during the course of this study or 4&#xD;
             months after receiving their last dose of study drug(s).&#xD;
&#xD;
        Exclusion criteria regarding special restrictions for males, even if surgically sterilized&#xD;
        (i.e. status post vasectomy)&#xD;
&#xD;
          -  Male patients, who do not agree to use an adequate method of contraception, starting&#xD;
             with the first dose of study therapy during the entire study treatment period and&#xD;
             through 4 months after the last dose of study drug. Note: Abstinence is acceptable if&#xD;
             this is the usual lifestyle and preferred contraception for the subject.&#xD;
&#xD;
          -  Male patients who intend to donate sperm during the course of this study or 4 months&#xD;
             after receiving their last dose of study drug(s).&#xD;
&#xD;
        Regulatory requirements&#xD;
&#xD;
          -  Age under 18 years at registration&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Subject without legal capacity who is unable to understand the nature, scope,&#xD;
             significance and consequences of this clinical trial&#xD;
&#xD;
          -  Simultaneous participation in another interventional clinical trial or participation&#xD;
             in any clinical trial involving administration of an investigational medicinal product&#xD;
             within 30 days prior to SHAPE trial beginning&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <phone>+49 341 97 13050</phone>
    <email>uwe.platzbecker@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Klinik IV - Hämatologie und Onkologie, Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentrum Hämatologie, Onkologie, Palliativmedizin, Helios Klinikum Berlin-Buch GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Niederland, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin III, Hämatologie, Onkologie, Stammzelltransplantation, Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathias Hänel, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämatologie/Internistische Onkologie, Onkologische Tagesklinik</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinischen Klinik und Poliklinik I / Hämatologie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01304</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Hämatologie, Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik und Poliklinik für Innere Medizin IV, Onkologie, Hämatologie, Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin II/Hämat. - Onkologie, Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian Scholl, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin II/ Hämatologie und Onkologie, Univ.Klinikum Schleswig-Holstein/Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, Hämostaseologie, Leipzig University</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <email>uwe.platzbecker@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Innere Medizin A/Hämatologie-Onkologie, Universitätsklinik Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Henrik Mikesch, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Hämatologie, Onkologie &amp; Stammzelltherapie, Helios-Klinikum Schwerin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Günther, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Innere Medizin III - Onko-, Häma- u. Palliativmedizin, Diakonie-Klinikum Schwäbisch Hall gGmbH</name>
      <address>
        <city>Schwäbisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abteilung für Hämatologie, Onkologie und Palliativmedizin, Robert-Bosch-Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaufmann, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Uwe Platzbecker</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Pevonedistat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

